148 related articles for article (PubMed ID: 9336049)
1. [Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 gram-negative bacteria].
Gales AC; Pignatari AC; Jones RN; Baretta M; Sader HS
Rev Assoc Med Bras (1992); 1997; 43(2):137-44. PubMed ID: 9336049
[TBL] [Abstract][Full Text] [Related]
2. [In vitro susceptibility testing of 446 clinical isolates of gram-positive bacteria to new quinolones, carbapenems and cephalosporins].
Cereda RF; Pignatari AC; Leme IL; Jones RN; Sader HS
Rev Assoc Med Bras (1992); 1996; 42(3):130-4. PubMed ID: 9138353
[TBL] [Abstract][Full Text] [Related]
3. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
Hsueh PR; Chen WH; Luh KT
Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
Pitkin DH; Sheikh W; Nadler HL
Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
7. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group.
Xu Y; Chen M; Biedenbach DJ; Deshpande LM; Jones RN
Diagn Microbiol Infect Dis; 1999 Oct; 35(2):135-42. PubMed ID: 10579094
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.
Karlowsky JA; Kelly LJ; Thornsberry C; Jones ME; Evangelista AT; Critchley IA; Sahm DF
Int J Antimicrob Agents; 2002 Jan; 19(1):21-31. PubMed ID: 11814764
[TBL] [Abstract][Full Text] [Related]
10. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
Sutherland CA; Nicolau DP
Clin Ther; 2015 Jul; 37(7):1564-71. PubMed ID: 26088525
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
[TBL] [Abstract][Full Text] [Related]
15. Gram-negative bacilli isolated from patients in intensive care unit: prevalence and antibiotic susceptibility.
Eltahawy AT
J Chemother; 1997 Dec; 9(6):403-10. PubMed ID: 9491839
[TBL] [Abstract][Full Text] [Related]
16. [In vitro antimicrobial activity of cefpirome compared to other broad-spectrum beta-lactam drugs against 804 clinical isolates from 9 Brazilian hospitals].
Sader HS; Mendes CM; Montelli A; Sampaio J; Segura AJ; Kesselring GL; Costa L; Ribeiro JE; Mamizuka E; Mimiça I
Rev Assoc Med Bras (1992); 1998; 44(4):283-8. PubMed ID: 9852647
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
Sader HS; Castanheira M; Mendes RE; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital.
Jean SS; Teng LJ; Hsueh PR; Ho SW; Luh KT
J Antimicrob Chemother; 2002 Jan; 49(1):69-76. PubMed ID: 11751769
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Christenson JC; Korgenski EK; Daly JA
J Antimicrob Chemother; 2000 Jun; 45(6):899-901. PubMed ID: 10837448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]